Beetham Thomas W. 4
4 · Viridian Therapeutics, Inc.\DE · Filed Sep 30, 2024
Insider Transaction Report
Form 4
Beetham Thomas W.
Chief Operating Officer
Transactions
- Purchase
Common Stock
2024-09-27$23.41/sh+5,000$117,050→ 6,000 total
Footnotes (1)
- [F1]Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on September 19, 2024 in transactions that were exempt under Rule 16b-3(c).